To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:6 Issue:2 Number:37 ISSN#:2564-2537
ACE Report #9045
Ace Report Cover Metabolic Disorders

Efficacy of combined teriparatide & denosumab vs. single-drug treatment for osteoporosis

How to Cite

OrthoEvidence. Efficacy of combined teriparatide & denosumab vs. single-drug treatment for osteoporosis. ACE Report. 2017;6(2):37. Available from:

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)

J Clin Endocrinol Metab. 2016 May;101(5):2023-30

Contributing Authors:
JN Tsai AV Uihlein SM Burnett-Bowie RM Neer NP Derrico H Lee ML Bouxsein BZ Leder

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


94 postmenopausal women with osteoporosis were randomized to receive either teriparatide, denosumab, or a combination of the two treatments. The purpose of this study was to determine the effectiveness of combined therapy with regards to bone microarchitecture and estimated strength. Findings indicated that combination therapy of teriparatide and denosumab significantly improved most volumetric bo...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.